These drugs are essential to prevention of rejection but come at a metabolic cost, disrupting glucose metabolism through several mechanisms, including downregulation of transcription of the adiponectin gene which can lead to greater risk for glucose intolerance
Not trace amounts
Healthcare professionals should be aware that: Patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should be carefully evaluated before prescribing Routine calcitonin measurement is not recommended for patients without risk factors, as per UK guidance [23] [24] Patients should be counselled about symptoms of thyroid tumours, including a neck mass, dysphagia, dyspnoea, or persistent hoarseness The theoretical risk must be balanced against the proven cardiovascular and metabolic benefits of these medicines in appropriate patient populations
Definition and Medical Classification Semaglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist
As research continues to clarify mechanisms, refine formulations and define long-term risks and benefits, GLP-1based therapies may ultimately serve as a model for a new generation of treatmentsones that work not by targeting a single pathway, but by engaging the bodys interconnected systems as a whole
